Here's Why Karyopharm Therapeutics Has a Unique Growth Opportunity
Cancer-drug maker Karyopharm Therapeutics (NASDAQ: KPTI) has seen phenomenal growth since early 2019, with its stock up more than 60% in a bit more than a year.
The 12-year-old company is pioneering novel drugs that will help treat patients with certain blood cancers or solid tumors. Over the past six months alone, the stock has generated gains of 72%. So what's generating all this buzz?
IMAGE SOURCE: GETTY IMAGES.
Source Fool.com